Why gene therapy filling is critical

Gene therapies can be life changing. The final manufacturing step, aseptic filling, deserves the same attention as the rest of your process. It’s critical to ensure it is done reproducibly, without contaminating or compromising quality all while minimizing line loss. The stakes are high – patients are waiting.

A cleanroom operator holds a filled and capped pharmaceutical vial

Resources

SA25 Aseptic Filling Workcell operated using HMI touchscreen

Hands off the goods

It’s time to adopt closed, automated aseptic filling processes for the drugs of today and tomorrow.

Closed robotic workcells

Learn how they differ from conventional systems and how your drug product operations can benefit.

Customer story: Emergent BioSolutions

How Emergent BioSolutions transitioned their commercial products to our gloveless filling platform.

Filling of nested vials inside the SA25 Aseptic Filling Workcell

Standardization and flexibility

You don’t have to choose between the two – and they actually complement each other.

Reduce risk with a closed, robotic process

Cytiva’s Aseptic Filling Workcells use an automated robotic process that removes the need for human intervention and allows them to be completely closed from end-to-end with no glove ports. This reduces the risk of contamination in gene therapy manufacturing and maintains drug product quality.

Operator observes vial filling process from outside the Cytiva Microcell Vial Filler

Scale quickly and economically

When developing potentially life-saving therapies, you want the ability to scale. Our standardized workcells can be added quickly, allowing you to scale out to move from development to commercialization. Our machines are also fitted with a dynamic peristaltic pump for fast, accurate filling that minimizes line loss.